DAL-302 (dal-GenE-2) Trial: A Phase 3, Double-Blind, Randomized Placebo Controlled Study To Evaluate The Effects Of Dalcetrapib On CV Risk In A Genetically Defined Population With Recent ACS

Grants and Contracts Details

StatusActive
Effective start/end date4/26/244/26/26

Funding

  • DalCor Pharmaceuticals Canada Incorporated: $2.00